☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Osimertinib
Insights+: Breakthrough Therapy Designation by the US FDA in 2020
March 11, 2021
AstraZeneca Reports the Results of Tagrisso (osimertinib) in P-III ADAURA Study for the Adjuvant Treatment of Patients Early-Stage...
September 21, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.